In this episode, Dr. Kumar talks about why case reports are important in rheumatology and introduces his Rheuminations column in the April issue, in which he talks about the types of cases that make a good case report and elements that go into a good report.
The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…
I often think about medical literature as a sprawling metropolis. There are towering skyscrapers of randomized controlled trials, lofty schools of systematic reviews and meta-analyses, and verdant parks of qualitative studies. Much less assuming are the case reports, which are sort of like homesteads for the majority of people who publish and contribute to the…
Independent, community-based rheumatologists and rheumatology professionals represent a critical part of the ACR and ARP. My immense respect for clinicians grew while watching my husband, who joined an independent practice after completing rheumatology fellowship. With admiration, I saw how he and his two dedicated partners cared for patients while simultaneously managing overhead and striving to…
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from North America. Patient Presentation A 3-year-old boy presented with a four-month history of rash and hand blisters….
A new study questions whether acetaminophen is a risk-free pain reliever for patients aged 65 and older, including those with osteoarthritis (OA). Although acetaminophen is often touted as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, a population-based cohort study found it carried an increased risk of peptic ulcers, bleeding and other side…
“What can I eliminate from my diet to cure my arthritis?” is the question every client with arthritis asks me. Numerous case reports document patients who achieved lower markers of inflammation and reduced pain and stiffness associated with the removal of one or two food groups from a diet, but historically, no compelling evidence has…
This year, rheumatology professionals in the U.S. and across the world will descend on the Windy City (Chicago) for ACR Convergence 2025. This meeting is the premier gathering place for up-to-date rheumatology education. Although the education sessions provide rich syntheses of evidence you can apply to your next patient, the real treasure is in the…
Here participants in the ACR’s Rheum With a (re)View program discuss how its mentors provided them with skills and knowledge that benefit their careers and rheumatology as a community.
New clinical features, opinion pieces and much more—outgoing Arthritis & Rheumatology Editor-in-Chief Daniel H. Solomon, MD, MPH, discusses how the journal has evolved and where it’s going.
As president elect of the Tennessee Medical Association (TMA), J. Eugene Huffstutter, MD, FACP, FACR, MACR, a rheumatologist with Arthritis Associates in Hixson, Tenn., says one of his priorities as the new president of the Tennessee Medical Association (TMA) is ensuring physicians can focus on practicing medicine without unnecessary obstacles. Dr. Huffstutter expresses concern about…
Based on decades of data from dietary and other lifestyle interventions, doctors have long known that significant weight loss can be an effective treatment for people who are overweight and have knee osteoarthritis (OA). One meta-analysis showed that OA pain, function and stiffness scores improved by 2% for every 1% in lost weight.1 But the…
Results from two studies found that deucravacitinib improved the signs and symptoms of patients with psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naive and those previously treated with a tumor necrosis factor α inhibitor.